Effectiveness of Ezetimibe Added to Ongoing Statin Therapy in Modifying Lipid Profiles and Low-Density Lipoprotein Cholesterol Goal Attainment in Patients of Different Races and Ethnicities: A Substudy of the Ezetimibe Add-On to Statin for Effectiveness Trial

September 2006
Mayo Clinic Proceedings;Sep2006, Vol. 81 Issue 9, p1177
Academic Journal
No abstract available.


Related Articles

  • A Community-Based, Randomized Trial of Ezetimibe Added to Statin Therapy to Attain NCEP ATP III Goals for LDL Cholesterol in Hypercholesterolemic Patients: The Ezetimibe Add-On to Statin for Effectiveness (EASE) Trial. Pearson, Thomas A.; Denke, Margo A.; McBride, Patrick E.; Battisti, Wendy P.; Brady, William E.; Palmisano, Joanne // Mayo Clinic Proceedings;May2005, Vol. 80 Issue 5, p587 

    OBJECTIVE: To determine the extent of reduction in low-density Ilpoproteln cholesterol (LDL-C) level and improvement in National Cholesterol Education Program Adult Treatment Panel III (NCEP ATP III) LDL-C goal attainment when ezetimibe was added to ongoing statin therapy in a diverse population...

  • Combination Therapy of Statins with Ezetimibe. Moriguchi, Emilio H.; Da Costa Vieira, José Luiz // Immunology, Endocrine & Metabolic Agents - Medicinal Chemistry;Jun2008, Vol. 8 Issue 2, p189 

    Ezetimibe is a cholesterol absorption inhibitors that blocks the intestinal absorption of cholesterol and biliary cholesterol without affecting the uptake of triglyceride or fat-soluble vitamins. The co-administration of ezetimibe with statin has been shown to produce significant incremental...

  • Impact of Ezetimibe on Atherosclerosis: Is the Jury Still Out? Al Badarin, Firas J.; Kullo, Iftikhar J.; Kopecky, Stephen L.; Thomas, Randal J. // Mayo Clinic Proceedings;Apr2009, Vol. 84 Issue 4, p353 

    Ezetimibe is a new lipid-lowering agent that inhibits Intestinal absorption of dietary cholesterol. It substantially lowers low-density lipoprotein cholesterol levels when used alone or in combination with statins. However, its effect on cardiovascular mortality remains unknown. We reviewed...

  • The pivotal role of cholesterol absorption inhibitors in the management of dyslipidemia. Al-Shaer, Moutasim H.; Choueiri, Nabil E.; Suleiman, Ehab S. // Lipids in Health & Disease;2004, Vol. 3, p22 

    Elevated low-density lipoprotein (LDL)-cholesterol is associated with a significantly increased risk of coronary heart disease. Ezetimibe is the first member of a new class of selective cholesterol absorption inhibitors. It impairs the intestinal reabsorption of both dietary and hepatically...

  • Ezetimibe Therapy for Dyslipidemia: An Update. Katsiki, Niki; Theocharidou, Eleni; Karagiannis, Asterios; Athyros, Vasilios G.; Mikhailidis, Dimitri P. // Current Pharmaceutical Design;May2013, Vol. 19 Issue 15-17, p3107 

    Ezetimibe, an inhibitor of intestinal cholesterol absorption, can decrease total cholesterol (TC), low density lipoprotein cholesterol (LDL-C), triglycerides (TGs) and apolipoprotein (apo) B levels and increase high-density lipoprotein cholesterol (HDL-C) levels. Apart from lipid-lowering,...

  • Ezetimibe/Simvastatin: A Guide to its Clinical Use in Hypercholesterolemia. Lyseng-Williamson, Katherine A. // American Journal of Cardiovascular Drugs;2012, Vol. 12 Issue 1, p49 

    Ezetimibe/simvastatin therapy combines two lipid-lowering compounds with complementary mechanisms of action, thereby blocking the two sources of plasma cholesterol and improving lipid profiles. Ezetimibe/ simvastatin is an effective and generally well tolerated adjunct to dietary therapy for...

  • Systematic Review: Comparative Effectiveness and Harms of Combination Therapy and Monotherapy for Dyslipidemia. Sharma, Mukul; Ansari, Mohammed T.; Abou-Setta, Ahmed M.; Soares-Weiser, Karla; Teik Chye Ooi; Sears, Margaret; Yazdi, Fatemeh; Tsertsvadze, Alexander; Moher, David // Annals of Internal Medicine;11/3/2009, Vol. 151 Issue 9, p622 

    Background: Statin therapy effectively prevents vascular disease, but treatment targets are often not achieved. Purpose: To compare the benefits and harms of high-dose statin monotherapy with those of combination therapy in adults at high risk for coronary disease. Data Sources: English-language...

  • Is newer better in cholesterol drugs?  // Consumer Reports on Health;Aug2003, Vol. 15 Issue 8, p10 

    Discusses the use of two cholesterol-lowering drugs, ezetimibe and extended-release lovastatin. Comparison of effectiveness of ezetimibe and statins; Use of ezetimibe in reducing low density lipoproteins; Advantage of low cost of lovastatin.

  • Changes in LDL-Clevels and goal attainment associated with addition of ezetimibe to simvastatin, atorvastatin, or rosuvastatin compared with titrating statin monotherapy. Foody, JoAnne M.; Toth, Peter P.; Tomassini, Joanne E.; Sajjan, Shiva; Ramey, Dena R.; Neff, David; Tershakovec, Andrew M.; Henry Hu; Tunceli, Kaan // Vascular Health & Risk Management;2013, Vol. 9, p719 

    Background: Many high-risk coronary heart disease (CHD) patients on statin monotherapy do not achieve guideline-recommended low-density lipoprotein cholesterol (LDL-C) goals, and combination lipid-lowering therapy may be considered for these individuals. The effect of adding ezetimibe to...

  • The NPC1L1 Inhibitor Ezetimibe in the Treatment of the Dyslipidemia in Patients Affected by the Metabolic Syndrome: Evidences and Perspectives. Anfossi, Giovanni; Frascaroli, Chiara; Bonomo, Katia; Chirio, Massimo; Giordanino, Chiara; Trovati, Mariella // Current Enzyme Inhibition;Oct2008, Vol. 4 Issue 3, p109 

    Ezetimibe is the first lipid-lowering drug which selectively inhibits the intestinal uptake of dietary and biliary cholesterol by binding to the cholesterol transporter protein Niemann-Pick C1 Like 1 (NPC1L1). This drug is an effective new tool for cholesterol lowering and allows to better...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics